Obesity evidence dossier
Nimacimab
A discontinued Phase 2 obesity antibody with non-significant low-exposure monotherapy efficacy but a small, company-reported add-on signal with semaglutide.
Total weight loss
1.5%
CBeyond · 200 mg weekly monotherapy · week 26 · Analysis not fully specified
Placebo-adjusted
1.3%
Difference from placebo in the same study when reported.
Study context
Peripherally restricted negative-allosteric-modulating anti-CB1 monoclonal antibody./Adults with obesity or overweight, without diabetes/136 participants across the study/26-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
CBeyond · 200 mg weekly monotherapy · 26 weeks
Adults with obesity or overweight, without diabetes. 136 participants across the study (not this dose arm alone).
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally. Modified intention-to-treat monotherapy result.
- Average weight loss
- 1.52%
- Placebo group
- 0.26% loss
- Beyond placebo
- 1.26 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Primary endpoint was not met (p=0.2699). The numerical score does not establish efficacy. Combination results are excluded.
Score: 70% × 6.1 total-loss points + 30% × 6.3 beyond-placebo points = 6/100, rounded. Conversion scales
Skye, CBeyond topline ↗Phase 2 · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
CBeyond: Analysis not fully specified. Modified intention-to-treat monotherapy result. Primary endpoint was not met (p=0.2699). The numerical score does not establish efficacy. Combination results are excluded.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Company-reported placebo-like monotherapy tolerability; GI adverse events were 27.0% with nimacimab versus 29.5% with placebo, and 57.1% with nimacimab-plus-semaglutide versus 66.7% with semaglutide alone. No treatment-associated increase in anxiety, insomnia, or depression was reported.
Main cautions
Small Phase 2a cohorts; company-reported topline data; monotherapy failed its primary endpoint; the program was discontinued/paused in Q2 2026.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.